盐酸缬更昔洛韦片在国内上市没？

The tablet, developed by Roche, is the first oral anti-cytomegalovirus infection drug for the treatment of retinitis. Valganciclovir hydrochloride is also approved for the prevention of cytomegalovirus infection after bone marrow, heart, liver, lung and other transplant surgeries. The general course of treatment is 3-6 months. Valganciclovir hydrochloride was first launched in the United States in 2001 and has been approved in most countries around the world. Are valganciclovir hydrochloride tablets available in China?

Valganciclovir hydrochloride tablets were launched in China in 2006 and are suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis and the prevention of CMV infection in high-risk solid organ transplant patients.

Valganciclovir hydrochloride is currently available in all major infectious disease hospitals and pharmacies in China. However, because it is an imported original drug, the price is relatively expensive. The domestic valganciclovir hydrochloride specification is 450mg-60 tablets/box, and the price is about US$2,250.

If patients feel that the price of valganciclovir hydrochloride in China is unaffordable, they can also choose valganciclovir hydrochloride, the original drug sold by Roche in India. The price is the lowest in the world, and it is also the most purchased drug by domestic and foreign patients. India's Vancevir (valganciclovir hydrochloride tablets, valgansiklovir) 450mg*60 tablets/box, priced at about US$750. Due to floating exchange rates, the price is not fixed. Please consult Medical Travel for specific prices.

Induction therapy of CMV retinitis: For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity. Maintenance treatment of CMV retinitis: After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis. Prevention of CMV infection in transplant patients: For patients who have received solid organ transplants, the recommended dosage is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.